Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa.

Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101496665 Publication Model: Print Cited Medium: Internet ISSN: 1654-9880 (Electronic) Linking ISSN: 16549880 NLM ISO Abbreviation: Glob Health Action Subsets: MEDLINE

Publication: <2016- > : Philadelphia, PA : Taylor & Francis
Original Publication: Häggeby : Co-Action Publishing

Tuberculosis*/drug therapy ; Tuberculosis, Multidrug-Resistant*; Cost of Illness ; Cross-Sectional Studies ; Gambia ; Health Care Costs ; Humans ; Longitudinal Studies ; Mozambique ; South Africa ; Tanzania ; World Health Organization

The WHO developed a generic 'TB patient cost survey' tool and a standardized approach to assess the direct and indirect costs of TB incurred by patients and their households, estimate the proportion of patients experiencing catastrophic costs, and measure the impact of interventions to reduce patient costs. While the generic tool is a facility-based cross-sectional survey, this standardized approach needs to be adapted for longitudinal studies. A longitudinal approach may overcome some of the limitations of a cross-sectional design and estimate the economic burden of TB more precisely. We describe the process of creating a longitudinal instrument and its application to the TB Sequel study, an ongoing multi-country, multi-center observational cohort study. We adapted the cross-sectional WHO generic TB patient cost survey instrument for the longitudinal study design of TB Sequel and the local context in each study country (South Africa, Mozambique, Tanzania, and The Gambia). The generic instrument was adapted for use at enrollment (start of TB treatment; Day 0) and at 2, 6, 12 and 24 months after enrollment, time points intended to capture costs incurred for diagnosis, during treatment, at the end of treatment, and during long-term follow-up once treatment has been completed. These time points make the adapted version suitable for use in patients with either drug-sensitive or drug-resistant TB. Using the adapted tool provides the opportunity to repeat measures and make comparisons over time, describe changes that extend beyond treatment completion, and link cost survey data to treatment outcomes and post-TB sequelae. Trial registration : ClinicalTrials.gov: NCT032516 August 1196, 2017. Abbreviations : DOTS: Directly observed treatment, short-course; DR-TB: Drug-resistant tuberculosis; MDR-TB: Multi-drug resistant tuberculosis; NTP: National Tuberculosis Programme; TB: Tuberculosis; USD: United States Dollar; WHO: World Health Organization.

PLoS One. 2014 Sep 30;9(9):e108654. (PMID: 25268951)
BMC Pulm Med. 2019 Jan 7;19(1):4. (PMID: 30616617)
BMC Med Res Methodol. 2013 Jul 31;13:100. (PMID: 23902644)
Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1129-1130. (PMID: 31718747)
Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1205-1212. (PMID: 31718757)
Eur Respir J. 2014 Jun;43(6):1763-75. (PMID: 24525439)
Value Health. 2006 Jul-Aug;9(4):253-61. (PMID: 16903995)
Int J Tuberc Lung Dis. 2019 Jun 1;23(6):756-763. (PMID: 31315710)
Soc Sci Med. 2018 Oct;215:7-15. (PMID: 30196149)
BMC Public Health. 2019 Jul 22;19(1):973. (PMID: 31331311)
Int J Tuberc Lung Dis. 2019 Jan 1;23(1):5-11. (PMID: 30674374)
Pharmacoeconomics. 2015 Sep;33(9):939-55. (PMID: 25939501)

001 International WHO_ World Health Organization

Keywords: Catastrophic total costs; TB sequelae; income; out-of-pocket; pre-treatment

Date Created: 20210125 Date Completed: 20210602 Latest Revision: 20210602

20240829

PMC7850383

10.1080/16549716.2020.1865625

33491593